Mizejewski G J
Molecular Medicine, Wadsworth Center, New York State Department of Health, Albany 12201-0509, USA.
Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38. doi: 10.1177/153537029922200203.
Tumor cells are characterized by uncontrolled growth, invasion to surrounding tissues, and metastatic spread to distant sites. Mortality from cancer is often due to metastasis since surgical removal of tumors can enhance and prolong survival. The integrins constitute a family of transmembrane receptor proteins composed of heterodimeric complexes of noncovalently linked alpha and beta chains. Integrins function in cell-to-cell and cell-to-extracellular matrix (ECM) adhesive interactions and transduce signals from the ECM to the cell interior and vice versa. Hence, the integrins mediate the ECM influence on cell growth and differentiation. Since these properties implicate integrin involvement in cell migration, invasion, intra- and extra-vasation, and platelet interaction, a role for integrins in tumor growth and metastasis is obvious. These findings are underpinned by observations that the integrins are linked to the actin cytoskeleton involving talin, vinculin, and alpha-actinin as intermediaries. Such cytoskeletal changes can be manifested by rounded cell morphology, which is often coincident with tumor transformation via decreased or increased integrin expression patterns. For the various types of cancers, different changes in integrin expression are further associated with tumor growth and metastasis. Tumor progression leading to metastasis appears to involve equipping cancer cells with the appropriate adhesive (integrin) phenotype for interaction with the ECM. Therapies directed at influencing integrin cell expression and function are presently being explored for inhibition of tumor growth, metastasis, and angiogenesis. Such therapeutic strategies include anti-integrin monoclonal antibodies, peptidic inhibitors (cyclic and linear), calcium-binding protein antagonists, proline analogs, apoptosis promotors, and antisense oligonucleotides. Moreover, platelet aggregation induced by tumor cells, which facilitates metastatic spread, can be inhibited by the disintegrins, a family of viper venom-like peptides. Therefore, adhesion molecules from the integrin family and components of angiogenesis might be useful as tumor progression markers for prognostic and for diagnostic purposes. Development of integrin cell expression profiles for individual tumors may have further potential in identifying a cell surface signature for a specific tumor type and/or stage. Thus, recent advances in elucidating the structure, function, ECM binding, and signaling pathways of the integrins have led to new and exciting modalities for cancer therapeutics and diagnoses.
肿瘤细胞的特征是生长失控、侵袭周围组织并转移至远处部位。癌症导致的死亡通常归因于转移,因为手术切除肿瘤可提高生存率并延长生存期。整合素是一族跨膜受体蛋白,由非共价连接的α和β链组成的异二聚体复合物构成。整合素在细胞间和细胞与细胞外基质(ECM)的黏附相互作用中发挥作用,并将信号从ECM转导至细胞内部,反之亦然。因此,整合素介导ECM对细胞生长和分化的影响。由于这些特性表明整合素参与细胞迁移、侵袭、进出血管以及血小板相互作用,所以整合素在肿瘤生长和转移中的作用显而易见。这些发现得到了以下观察结果的支持:整合素通过踝蛋白、纽蛋白和α辅肌动蛋白作为中介与肌动蛋白细胞骨架相连。这种细胞骨架变化可表现为细胞形态变圆,这通常与通过整合素表达模式降低或增加而发生的肿瘤转化同时出现。对于各种类型的癌症,整合素表达的不同变化还与肿瘤生长和转移相关。导致转移的肿瘤进展似乎涉及使癌细胞具备与ECM相互作用的适当黏附(整合素)表型。目前正在探索针对影响整合素细胞表达和功能的疗法,以抑制肿瘤生长、转移和血管生成。此类治疗策略包括抗整合素单克隆抗体、肽类抑制剂(环状和线性)、钙结合蛋白拮抗剂、脯氨酸类似物、凋亡促进剂和反义寡核苷酸。此外,肿瘤细胞诱导的血小板聚集促进了转移扩散,而蝰蛇毒样肽家族的去整合素可抑制这种聚集。因此,整合素家族的黏附分子和血管生成成分可能作为肿瘤进展标志物用于预后和诊断目的。针对个体肿瘤开发整合素细胞表达谱可能在识别特定肿瘤类型和/或阶段的细胞表面特征方面具有更大潜力。因此,在阐明整合素的结构、功能、ECM结合和信号通路方面的最新进展为癌症治疗和诊断带来了新的、令人兴奋的模式。